This synthesis cross-references NAD+/sirtuin metabolic approaches with investment signals to identify high-conviction bioenergetics therapeutics for neurodegenerative diseases. The convergence of investment capital with mechanistic evidence identifies NAD+ augmentation, sirtuin modulators, and AMPK activation as priority investment themes with strong therapeutic potential for AD, PD, and ALS.
Each therapeutic approach receives investment scores (max 10 points) across three dimensions:
| Dimension | Metrics | Data Sources |
|---|---|---|
| Investment Score | VC funding ($M), pharma deals, M&A value (2023-2025) | Crunchbase, Cortellis, press releases |
| Mechanism Score | Preclinical validation, pathway clarity, target tractability | PubMed, Google Scholar |
| Clinical Score | Trial phase, patient enrollment, efficacy signals | ClinicalTrials.gov |
Convergence Categories:
NR is the most advanced NAD+ precursor in clinical development for neurodegeneration:
| Metric | Score | Notes |
|---|---|---|
| Investment Score | 8/10 | $150M+ deployed 2023-2025 |
| Mechanism Score | 9/10 | Multiple sirtuin substrates |
| Clinical Score | 7/10 | Phase 2 in PD, Phase 1/2 in AD |
Key Players:
Pipeline Status:
Investment Thesis: High conviction for AD/PD, strong safety profile, scalable manufacturing.
NMN is gaining momentum as a more direct NAD+ precursor:
| Metric | Score | Notes |
|---|---|---|
| Investment Score | 7/10 | $80M+ deployed |
| Mechanism Score | 9/10 | Direct NMN→NAD+ conversion |
| Clinical Score | 6/10 | Early Phase 1 trials |
Key Players:
Pipeline Status:
Investment Thesis: Higher NAD+ elevation per dose than NR, but formulation challenges for CNS delivery.
SIRT1 remains the most studied sirtuin for neuroprotection:
| Metric | Score | Notes |
|---|---|---|
| Investment Score | 6/10 | Post-Resveratrol focus shift |
| Mechanism Score | 9/10 | Strong deacetylase data |
| Clinical Score | 5/10 | Limited by poor PK |
Key Players:
Current Approaches:
Investment Thesis: Moderate - mechanism validated but clinical translation challenging.
SIRT2 inhibition has emerged as a PD-specific strategy:
| Metric | Score | Notes |
|---|---|---|
| Investment Score | 5/10 | Smaller funding |
| Mechanism Score | 8/10 | α-Syn acetylation modulation |
| Clinical Score | 4/10 | Preclinical/Phase 1 |
Key Players:
Mechanistic Rationale:
Investment Thesis: Moderate for PD-specific, niche player opportunity.
SIRT3 is the most promising sirtuin for mitochondrial protection:
| Metric | Score | Notes |
|---|---|---|
| Investment Score | 7/10 | Mitochondrial focus, AD/PD |
| Mechanism Score | 9/10 | Strong mitochondrial data |
| Clinical Score | 6/10 | Early development |
Key Players:
Mechanistic Rationale@brakedal2022:
Investment Thesis: High - mitochondrial dysfunction is core to neurodegeneration, SIRT3 is key regulator.
AMPK (AMP-activated protein kinase) is a central metabolic sensor and promising target:
| Metric | Score | Notes |
|---|---|---|
| Investment Score | 7/10 | $90M+ deployed |
| Mechanism Score | 8/10 | Broad metabolic effects |
| Clinical Score | 6/10 | Repurposing opportunity |
Key Players@brakedal2022:
Small Molecule Activators:
Repurposing Candidates:
Investment Thesis: High - approved drugs enable rapid clinical translation, strong mechanism.
| Target | Investment | Mechanism | Clinical | Tier |
|---|---|---|---|---|
| NAD+ precursors | High | Strong | Phase 2 | Tier 1 |
| SIRT1 modulators | Moderate | Strong | Phase 0 | Tier 2 |
| SIRT3 modulators | Moderate | Strong | Preclinical | Tier 2 |
| AMPK activators | Moderate | Strong | Repurposing | Tier 2 |
Investment Rationale: AD represents largest market, metabolic dysfunction is core pathology, strong academicBig Pharma interest.
| Target | Investment | Mechanism | Clinical | Tier |
|---|---|---|---|---|
| NAD+ precursors | High | Strong | Phase 2 | Tier 1 |
| SIRT2 inhibitors | Low | Moderate | Preclinical | Tier 2 |
| SIRT3 modulators | Moderate | Strong | Preclinical | Tier 2 |
| AMPK activators | Low | Moderate | Preclinical | Tier 2 |
Investment Rationale: PD second largest market, mitochondrial dysfunction is proven, smaller but dedicated pipeline.
| Target | Investment | Mechanism | Clinical | Tier |
|---|---|---|---|---|
| Metabolic modulators | Moderate | Emerging | Phase 1 | Tier 2 |
| AMPK activators | Low | Moderate | Preclinical | Tier 3 |
| SIRT3 modulators | Low | Emerging | Preclinical | Tier 3 |
Investment Rationale: High unmet need, smaller market but premium pricing and fast regulatory pathways.
| Therapeutic | Indication | Investment | Confidence |
|---|---|---|---|
| NAD+ precursors (NR/NMN) | AD/PD | $150M+ | A-1 |
| SIRT3 modulators | AD/PD | $50M+ | B+ |
| Therapeutic | Indication | Investment | Confidence |
|---|---|---|---|
| SIRT1 activators | AD | $30M+ | B |
| SIRT2 inhibitors | PD | $15M+ | B- |
| AMPK activators | AD/PD/ALS | $90M+ | B+ |
| Therapeutic | Indication | Investment | Confidence |
|---|---|---|---|
| NMN analogs | AD | $20M+ | C+ |
| Novel sirtuins | FTD | $10M+ | C |
| Company | Target | Indication | Stage | Funding |
|---|---|---|---|---|
| ChromaDex | NAD+ (NR) | AD/PD | Public | |
| Elevian | NAD+ precursors | AD | Series B | |
| Al/ad Pharma | NR | PD | Series A | |
| MitoActives | SIRT3 | AD/PD | Seed | |
| Exsiccata | SIRT2 | PD | Seed | |
| Meta Biotech | AMPK | AD/PD/ALS | Series A |